Targeting the Epidermal Growth Factor Receptor in Solid Tumor Malignancies

Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance

(2015) Kimmo J. Hatanpaa et al.   NEOPLASIA

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors

(2011) J.- C. Soria et al.   ANNALS OF ONCOLOGY

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

(2011) C. Bokemeyer et al.   ANNALS OF ONCOLOGY

Monoclonal antibody blockade of IL-2 receptor   during lymphopenia selectively depletes regulatory T cells in mice and humans

(2011) D. A. Mitchell et al.   BLOOD

Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial

(2011) Mogens Bernsdorf et al.   BREAST CANCER RESEARCH AND TREATMENT

Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile

(2011) Greta Garrido et al.   CANCER BIOLOGY & THERAPY

Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic Antibody Mixture Directed against Epidermal Growth Factor Receptor

(2011) Niels Jørgen Østergaard Skartved et al.   CLINICAL CANCER RESEARCH

Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development

(2011) Rodrigo Dienstmann et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer

(2011) Giulio Metro et al.   Expert Review of Anticancer Therapy

Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial

(2011) Richard H. de Boer et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2011) Ronald B. Natale et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

(2011) Roy S Herbst et al.   LANCET

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

(2011) Jean-Pascal Machiels et al.   LANCET ONCOLOGY

Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma

(2010) E. G. Van Meir et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188-Re in adult recurrent high-grade glioma

(2010) Angel Casaco et al.   CANCER BIOLOGY & THERAPY

Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy

(2010) Gwyn Bebb et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sym004: A Novel Synergistic Anti-Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy

(2010) M. W. Pedersen et al.   CANCER RESEARCH

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies

(2010) B. Kuenen et al.   CLINICAL CANCER RESEARCH

Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer

(2010) M. Cristofanilli et al.   CLINICAL CANCER RESEARCH

Could Autoimmunity Be Induced by Vaccination?

(2010) Simonetta Salemi et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

(2010) José María Viéitez et al.   INVESTIGATIONAL NEW DRUGS

A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies

(2010) Benoit You et al.   INVESTIGATIONAL NEW DRUGS

Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)

(2010) Hai T. Tran et al.   INVESTIGATIONAL NEW DRUGS

Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099

(2010) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer

(2010) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

(2010) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

(2010) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase II study of anti–epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme

(2010) Linna Li et al.   JOURNAL OF NEUROSURGERY

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

(2010) Roy S Herbst et al.   LANCET ONCOLOGY

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

(2010) Federico Cappuzzo et al.   LANCET ONCOLOGY

A phase I study of nimotuzumab in combination with radiotherapy in stages IIB–IV non-small cell lung cancer unsuitable for radical therapy: Korean results

(2010) Hye Jin Choi et al.   LUNG CANCER

Structural Evidence for Loose Linkage between Ligand Binding and Kinase Activation in the Epidermal Growth Factor Receptor

(2010) C. Lu et al.   MOLECULAR AND CELLULAR BIOLOGY

Spatial control of EGF receptor activation by reversible dimerization on living cells

(2010) Inhee Chung et al.   NATURE

Epidermal growth factor receptor signaling in liver cell proliferation and apoptosis

(2009) Roland Reinehr et al.   BIOLOGICAL CHEMISTRY

A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer

(2009) Olivier Rixe et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Humanized immunotoxins: A new generation of immunotoxins for targeted cancer therapy

(2009) Mrudula Mathew et al.   CANCER SCIENCE

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

(2009) K.-K. Wong et al.   CLINICAL CANCER RESEARCH

Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects

(2009) Jorg Hartmann et al.   CURRENT DRUG METABOLISM

Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

(2009) J. Simon W. Stewart et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

(2009) Robert Pirker et al.   LANCET

The cancer vaccine roller coaster

(2009) Bruce Goldman et al.   NATURE BIOTECHNOLOGY

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

The EGFR network in bone biology and pathology

(2009) Marlon R. Schneider et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Structure-Based View of Epidermal Growth Factor Receptor Regulation

(2008) Kathryn M. Ferguson   Annual Review of Biophysics

Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization

(2008) Judith Schmiedel et al.   CANCER CELL

Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients

(2008) C. J. Wheeler et al.   CANCER RESEARCH

Association of epidermal growth factor receptor (EGFR) gene mutations withEGFRamplification in advanced non-small cell lung cancer

(2008) Ryotaro Morinaga et al.   CANCER SCIENCE

Postoperative Adjuvant Dendritic Cell-Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme

(2008) S. De Vleeschouwer et al.   CLINICAL CANCER RESEARCH

EGFR family: Structure physiology signalling and therapeutic targets†

(2008) Antony W. Burgess   GROWTH FACTORS

Toxicology Study of Repeat Intracerebral Administration of a Measles Virus Derivative Producing Carcinoembryonic Antigen in Rhesus Macaques in Support of a Phase I/II Clinical Trial for Patients with Recurrent Gliomas

(2008) Rae Myers et al.   HUMAN GENE THERAPY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

(2008) J. Randolph Hecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

(2008) Carsten Bokemeyer et al.   JOURNAL OF CLINICAL ONCOLOGY

Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines

(2008) Robert J. Schmittling et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors

(2008) John H. Sampson et al.   NEURO-ONCOLOGY

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE

The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility

(2008) J. J. Lammerts van Bueren et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma

(2008) John H. Sampson et al.   SEMINARS IN IMMUNOLOGY

Single Chain Epidermal Growth Factor Receptor Antibody Conjugated Nanoparticles for in vivo Tumor Targeting and Imaging

(2008) Lily Yang et al.   Small

Structural Basis for EGF Receptor Inhibition by the Therapeutic Antibody IMC-11F8

(2008) Shiqing Li et al.   STRUCTURE